Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04932746
Other study ID # UDMS-Anesth-01-2021
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2021
Est. completion date February 1, 2023

Study information

Verified date February 2023
Source Damascus University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The children who will undergo OLV (one lung ventilation) through general anesthesia will be divided into two groups: The first will be intravenous infusion of dexmedetomidine at 0.4 mcg / kg / hour, and the second will be intravenous infusion of normal saline. We will take three samples of arterial blood gas (ABG) during the surgery at certain times. We record the hemodynamic values, PaO2, and calculate the value of the shunt Qs / Qt.


Description:

Lung isolation or one lung ventilation OLV means the mechanical separation of the lungs with independent ventilation of one lung from the other, in order to provide a suitable space for the work of the surgeon, and to protect a healthy lung from bleeding or edema caused by lung damage. OLV can lead to a mismatch in the ventilation / perfusion (V / Q) ratio resulting in increased intrapulmonary shunt as well as hypoxia. Hypoxic pulmonary vasoconstriction HPV is the most important preventive mechanism against hypoxemia, as blood flow moves from the unventilated lung to the ventilated lung to maintain an adequate arterial oxygen transport rate, HPV is a defense mechanism against hypoxia as it reduces pulmonary shunt. So that there is less oxygen drop than expected. HPV reaches its maximum effect in 15 minutes, resulting in decreased pulmonary shunt, homogenization of ventilation / perfusion ratio, and improved oxygen delivery. HPV is affected by various factors: changes in pulmonary pressure, alkalosis, vasodilators, anesthetic agents etc. Among these factors, anesthetic inhaled gases have the greatest effect on HPV. Pulmonary shunt: It is the sum of the physiological shunt (poorly ventilated air sacs) and the anatomical shunt and the pulmonary shunt fraction (Qs/Qt) is calculated from the equation Qs/Qt = (CcO2 - CaO2)/(CcO2 - CvO2) Qs: blood flow through the shunt, Qt : total blood flow, Cc'O2 : pulmonary capillary content of O2, CaO2 : arterial content of O2, CvO2 : venous mixed content of O2 100% O2 test: often performed in a cardiac catheterization lab, operating room, or ICU, the patient breathes 100% O2 until nitrogen is washed out from their lungs (20 minutes). The oxygen concentration even in poorly ventilated units will approach 100%. This means that the partial pressure and blood saturation are equal in the poorly ventilated and well-ventilated alveolar units, thus the physiological pulmonary shunt is canceled and the anatomical pulmonary shunt remains After lung isolation and OLV application, we perform anesthesia maneuvers on the ventilator and adjust the applied ventilators in order to maintain adequate oxygenation of the patient: increased PEEP, increased FLOW, increased tidal volume Vt, increased Pmax, increased FiO2, thus eliminating the physiological pulmonary shunt and the anatomical pulmonary shunt remains, in total we apply 100% O2 testing. Dexmedetomidine is a selective agonist for α2 receptors whose affinity for α2 receptors is eight times more than clonidine. At a dose of 0.3 mg / kg it activates protein G and inhibits norepinephrine secretion. When given in larger doses or infusion it stimulates the peripheral α2 receptors; It reduces the levels of norepinephrine in the plasma by more than 90%, thus reducing the cells' metabolism and their need for oxygen.Sympathetic blocker: Reduces heart rate, blood pressure and oxygen consumption of the heart muscle. Studies have shown that alpha-adrenergic blockade abolished pulmonary vasoconstriction that responds to norepinephrine but not to hypoxia. That is, it does not affect the blood supply and HPV of the unventilated lung, widens the blood vessels of the ventilated lung, and reduces the anesthetic requirements (affecting HPV); Reduces 30% of the need for propofol; It reduces desflurane concentration and its subsequent inhibitory effect on HPV. It may also lead to transient increases in pulmonary artery pressure related to its direct effects on vascular smooth muscle through alpha-adrenergic receptors.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date February 1, 2023
Est. primary completion date February 1, 2023
Accepts healthy volunteers No
Gender All
Age group 1 Day to 12 Years
Eligibility Inclusion Criteria: 1. As per the American Society of Anesthesiologists (ASA) classification I-I physical condition children undergoing thoracic surgery with OLV. 2. From one day old to 12 years old. 3. There is no prejudice in terms of gender. 4. This study practically does not exclude any child who will undergo OLV even in the presence of cardiac, renal or hepatic diseases. Or even in the presence of cardiac stimulants and supports (dopamine or dopamine), provided that the general condition is stable, which allows surgery and OLV. Exclusion Criteria: 1. Premature infants: due to immaturity of the lung and insufficient formation of the surfactant. 2. Cystic Fibrosis: The depressor for surfactant and lung immaturity is not permitted to perform the OLV technique 3. There is no contraindication for the administration of dexmedetomidine in children except those who show signs of allergy to the dexmedetomidine. 4. This study does not exclude practically any child who will undergo OLV. 5. During operating surgery: The child is excluded from the study if hypoxia occurs (SpO2 <90%) and did not respond to maneuvers and anesthetic techniques (Increase PEEP Increase the FLOW, Tidal volume, increase Vt, Pmax increased pressure, FiO2 increased) Then the lungs are periodically ventilated with positive pressure, and the OLV technique is switched off and the child is excluded from the pilot study. 6. During operating surgery: If there is a drop-in heart rate less than 60 beats / minute and it does not respond to atropine or an increased dose of Cardiac tonics (dopamine). At this time the infusion of dexmedetomidine is stopped, it is assumed that there is no very slow pulse, and if it does, it is likely that the primary cardiac lesion is the cause.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dexmedetomidine
Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine or placebo) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL. It begins with infusion of 4 ml within 10 minutes and then continues infusion, depending on the child's weight, at 1.6 ml / kg / h. All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique. The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is.
Placebo
The same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol

Locations

Country Name City State
Syrian Arab Republic University Children's Hospital Damascus

Sponsors (2)

Lead Sponsor Collaborator
Damascus University University Children's Hospital

Country where clinical trial is conducted

Syrian Arab Republic, 

References & Publications (9)

Asri S, Hosseinzadeh H, Eydi M, Marahem M, Dehghani A, Soleimanpour H. Effect of Dexmedetomidine Combined with Inhalation of Isoflurane on Oxygenation Following One-Lung Ventilation in Thoracic Surgery. Anesth Pain Med. 2020 Feb 12;10(1):e95287. doi: 10.5812/aapm.95287. eCollection 2020 Feb. — View Citation

Huang SQ, Zhang J, Zhang XX, Liu L, Yu Y, Kang XH, Wu XM, Zhu SM. Can Dexmedetomidine Improve Arterial Oxygenation and Intrapulmonary Shunt during One-lung Ventilation in Adults Undergoing Thoracic Surgery? A Meta-analysis of Randomized, Placebo-controlled Trials. Chin Med J (Engl). 2017 Jul 20;130(14):1707-1714. doi: 10.4103/0366-6999.209891. — View Citation

Lin J, Li JB, Lu Z. Clinical application and effect of dexmedetomidine in combination with continuous positive airway pressure on one-lung ventilation in lung surgery of elder patients. Pak J Pharm Sci. 2018 Nov;31(6(Special)):2879-2883. — View Citation

Meng J, Lv Q, Yao J, Wang S, Yang K. Effect of Dexmedetomidine on Postoperative Lung Injury during One-Lung Ventilation in Thoracoscopic Surgery. Biomed Res Int. 2020 Oct 5;2020:4976205. doi: 10.1155/2020/4976205. eCollection 2020. — View Citation

Shen Q, Xu G, Liu J, Wang L, Zhou Y, Yu Y, Lv C, Liu X. Dexmedetomidine alleviates non-ventilation associated lung injury via modulating immunology phenotypes of macrophages. Life Sci. 2020 Oct 15;259:118249. doi: 10.1016/j.lfs.2020.118249. Epub 2020 Aug 13. — View Citation

Sheybani S, Attar AS, Golshan S, Sheibani S, Rajabian M. Effect of propofol and isoflurane on gas exchange parameters following one-lung ventilation in thoracic surgery: a double-blinded randomized controlled clinical trial. Electron Physician. 2018 Feb 25;10(2):6346-6353. doi: 10.19082/6346. eCollection 2018 Feb. — View Citation

Wang J, Yi X, Jiang L, Dong H, Feng W, Wang S, Chu C. Protective effects of dexmedetomidine on lung in rats with one-lung ventilation. Exp Ther Med. 2019 Jan;17(1):187-192. doi: 10.3892/etm.2018.6952. Epub 2018 Nov 9. — View Citation

Xie Y, Jiang W, Zhao L, Wu Y, Xie H. Effect of dexmedetomidine on perioperative inflammation and lung protection in elderly patients undergoing radical resection of lung cancer. Int J Clin Exp Pathol. 2020 Oct 1;13(10):2544-2553. eCollection 2020. — View Citation

Xu B, Gao H, Li D, Hu C, Yang J. Nebulized dexmedetomidine improves pulmonary shunt and lung mechanics during one-lung ventilation: a randomized clinical controlled trial. PeerJ. 2020 Jun 5;8:e9247. doi: 10.7717/peerj.9247. eCollection 2020. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of change in PaO2 during surgery PaO2 : The partial pressure of oxygen The partial pressure of oxygen, also known as PaO2, is a measurement of oxygen pressure in arterial blood. It reflects how well oxygen is able to move from the lungs to the blood Three measurements will be taken over three times: T1: 10 min after induction of anesthesia and before OLV, T2: 10 min after lung isolation and OLV single lung ventilation, and T3: 60 min after OLV procedure.
Primary Evaluation of change in Qs/Qt during surgery. Qs/Qt: is a measurement of pulmonary shunt. Qs: blood flow through the shunt, Qt : total blood flow. It describes the percentage of blood that reaches the left side of the heart without picking up oxygen. The pulmonary shunt fraction (Qs/Qt) is calculated from the equation Qs/Qt = (CcO2 - CaO2)/(CcO2 - CvO2)
Parameters we need to the equation:
Measurement of arterial blood gases ABG from arteries (radial or aorta) and the values it provides:
PaO2: partial pressure of arterial oxygen
SaO2: the degree of oxygen saturation of arterial hemoglobin
Hb: hemoglobin
Measurement of ABG from the pulmonary artery or from the right atrium via central catheter
PvO2: partial pressure of venous oxygen
SvO2: the degree of oxygen saturation of venous hemoglobin
Hb: hemoglobin
The following values
PB = (759 ~ 760) atmospheric pressure
PH2O = 47 water vapor pressure at a body temperature of 37
RQ = 0.8: RER = respiratory exchange rate when anesthetized
FiO2 The Fraction of Inspired Oxygen
Three measurements will be taken over three times: T1: 10 min after induction of anesthesia and before OLV, T2: 10 min after lung isolation and OLV single lung ventilation, and T3: 60 min after OLV procedure.
Secondary Evaluation of change in CaO2 during surgery CaO2 :arterial content of O2. CaO2 = (PaO2 × 0.0031) + (Hb × 1.36 × SaO2) Three measurements will be taken over three times: T1: 10 min after induction of anesthesia and before OLV, T2: 10 min after lung isolation and OLV single lung ventilation, and T3: 60 min after OLV procedure.
Secondary Evaluation of change in CvO2 during surgery CvO2 :venous mixed content of O2. CvO2 = (PvO2 × 0.0031) + (Hb × 1.36 × SvO2) Three measurements will be taken over three times: T1: 10 min after induction of anesthesia and before OLV, T2: 10 min after lung isolation and OLV single lung ventilation, and T3: 60 min after OLV procedure.
Secondary Evaluation of change in Cc'O2 during surgery Cc'O2 : pulmonary capillary content of O2. CcO2 = ([FiO2 × (PB -PH2o) - PaCO2/RQ] × 0.0031) + (Hb × 1.36) Three measurements will be taken over three times: T1: 10 min after induction of anesthesia and before OLV, T2: 10 min after lung isolation and OLV single lung ventilation, and T3: 60 min after OLV procedure.
See also
  Status Clinical Trial Phase
Recruiting NCT04072419 - Application of Enhanced Recovery After Surgery for Congenital Esophageal Atresia During Perioperative Period
Withdrawn NCT03127345 - Omega 3 Fatty Acid Treatment for Pediatric Musculoskeletal Health Phase 2
Completed NCT00226044 - Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants. Phase 3
Completed NCT03615495 - Flourish™ Pediatric Esophageal Atresia
Recruiting NCT05995171 - Long Term Outcome of Easophageal Atresia : Transmics Profiles in Adolescence
Completed NCT04901546 - Esophageal Atresia: a Natural Experiment of the Effects of Oral Inoculation on the Gut Microbiome N/A
Recruiting NCT03730454 - Transanastomotic Tube for Proximal Esophageal Atresia With Distal Tracheoesophageal Fistula Repair N/A
Recruiting NCT03455881 - Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients
Completed NCT05527873 - Respiratory Complications of Operated Esophageal Atresia in Children
Not yet recruiting NCT04259528 - Endoscopic Ultrasound Findings in Esophageal Atresia Following Surgical Repair N/A
Recruiting NCT06073158 - Molecular Signatures of Esophageal Atresia N/A
Not yet recruiting NCT03999008 - Oral Viscous Budesonide in Anastomotic Stricture After Esophageal Atresia Repair (OVB in EA) N/A
Completed NCT03415893 - High-resolution Esophageal Manometry N/A
Not yet recruiting NCT03023865 - Individualized Management for Long Gap Esophageal Atresia N/A
Recruiting NCT02883725 - National Register of Oesophageal Atresia
Not yet recruiting NCT04136795 - Evaluation of the Respiratory Impact After Conventional or Minimally Invasive Esophageal Atresia Surgery
Recruiting NCT03619408 - Management of Esophagitis Following Repair of Esophageal Atresia
Completed NCT05129930 - Fluid Overload and Pulmonary Function
Completed NCT02033772 - Prospective Data Collection of Patients < 6 Months of Age Undergoing Thoracoscopic Surgery N/A
Recruiting NCT03767673 - Cardiorespiratory Performance and Pulmonary Microbiome in Patients After Repair of Esophageal Atresia N/A